INFLUENCE OF PULMONARY HYPERTENSION ON CLINICAL COURSE AND PROGNOSIS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Aim. Evaluation of clinical specifics, predictors of repeat hospitalizations and mortality in chronic obstructive pulmonary disease (COPD) patients according to pulmonary hypertension (PH) severity grade.

Material and methods. To the study, 288 COPD patients included (II-IV severity grade, GOLD 2016; males 276, females 12; mean age 59,5±9,27 y. o., smoking 23,1±11,42 pack/years; 2,4±0,89 exacerbations annually, body mass index (BMI) 27,2±12,06 kg/m²). According to the presence and grade of systolic pressure increase in pulmonary artery (SPPA) the patients were selected to three groups: 1st — with no PH (SPPA <40 mmHg, n=168), 2nd — with moderate PH (SPPA 40-55 mmHg, n=101), 3rd — with severe PH (SPPA >55 mmHg, n=19).

Results. Increase of SPPA was found in 120 (41,7%) patients: moderate PA — in 101 (35,1%), severe PH — 19 (6,6%). It was shown that the presence and severity of PH do increase the severity of clinical signs of COPD, hemodynamic disorders, increase the rate of repeat hospitalizations and mortality rate. The predictors of repeat hospitalizations in COPD patients are increased SPPA and C-reactive protein concentration (CRP); mortality predictors are severity of symptoms by CAT, Borg dyspnea, number of exacerbations during one year, size of the right atrium, grade of SPPA increase, CRP concentration, fibrinogen, N-terminal precursors of C-natriuretic peptide (NT-proCNP) and brain peptide (NT-proBNP) in the blood.

Conclusion. PH in COPD patients in most cases is moderate, and it worsens the clinical picture, hemodynamic disorders, shows only moderate correlation with breathing disorders, increases the rate of rehospitalizations and mortality risk. The survival rate of COPD and PH patients depends on the severity.

1. Global Initiative for Chronic Obstructive Lung Disease, 2018. http://goldcopd.org.

2. Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD 2014; 9 (12): 963-74. DOI: 10.2147/COPD.S67283.

3. Avdeev SN. Pulmonary hypertension associated with lung diseases. In: Chasova I E, Martynyuk TV, eds. Pulmonary hypertension. Moscow, M.: Practice, 2015: 525-62. (In Russ.) ISBN 978-5-89816-138-5.

4. Avdeev SN. Idiopathic pulmonary fibrosis: a new paradigm. Therapeutic archive 2017; 89 (1): 112-22. (In Russ.) DOI: 10.17116/terarkh2017891112-122.

5. Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical practice guidelines for the diagnosis and treatment of pulmonary hypertension. Therapeutic archive 2014; 9: 4-23. (In Russ.)

6. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 2005; 172: 189-94. DOI: 10.1164/rccm.200401-006OC.

7. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J 2016; 37 (1): 67-119. DOI: 10.1093/eurheartj/ehv317.

8. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol 2013; 62 (25, Suppl. D): 110-6. DOI: 10.1016/j.jacc.2013.10.036.

9. Neklyudova GV, Avdeev SN, Baymakhanova GE. Chronic obstructive pulmonary disease and pulmonary hypertension: brain natriuretic peptide as a marker of pulmonary hypertension. Pulmonology 2013; 3: 31-5. (In Russ.)

10. Kessler R, Oswald-Mammosser M. Does lung volume reduction surgery compromise the pulmonary circulation? Am. J. Respir. Crit. Care Med 1999; 160: 1429-30. DOI: 10.1164/ajrccm.160.4.16040_3.

11. Sims MW, Margolis DJ, Localio AR, et al. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009; 136: 412-9. DOI: 10.1378/chest.08-2739.

12. Cavaillès A, Brinchault-Rabin G, Dixmier A. Comorbidities of COPD. Eur. Respir. Rev 2013; 22: 454-75. DOI: 10.1183/09059180.00008612.

13. Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J. Heart Lung Transplant 2012; 31: 373-80. DOI: 10.1016/j.healun.2011.11.020.

14. Nekrasov AA, Kuznetsov AN, Melnichenko OV, Kabanova TI. Heart Remodeling in chronic obstructive pulmonary disease with different degree of pulmonary hypertension in the application of ACE inhibitors. Pulmonology 2012; 2: 52-5. (In Russ.)

15. Moreno A, Monton C, Belmonte Y, et al. Causes of death and risk factors for mortality in patients with severe chronic obstructive pulmonary disease. Arch. Bronconeumol 2009; 45 (4): 181-6. DOI: 10.1016/j.arbres.2008.09.004.